妊娠早期青蒿素衍生物与奎宁治疗及非洲和亚洲不良妊娠结局风险:观察性研究的Meta分析
该Meta分析纳入5项前瞻性观察性研究共30618例妊娠,比较妊娠早期使用青蒿素衍生物与奎宁或未抗疟治疗者的流产、死产和重大先天畸形风险。结果显示青蒿素与奎宁相比未增加流产或死产风险,重大先天畸形患病率两组相似(青蒿素1.5% vs 奎宁1.2%)。
要点
- 妊娠早期青蒿素暴露与奎宁相比,流产风险无显著差异(aHR=0.73,95%CI 0.44-1.21)。
- 死产风险aHR=0.29(95%CI 0.08-1.02),妊娠丢失aHR=0.58(95%CI 0.36-1.02),均未达统计学显著。
- 重大先天畸形患病率青蒿素组1.5% vs 奎宁组1.2%,两组相似。
核心结论
- 与奎宁相比,妊娠早期青蒿素治疗未增加流产或死产风险。
- 数据有限,但显示治疗组间重大先天畸形患病率无差异。
- 作者认为3天青蒿素联合疗法治疗早期妊娠疟疾的获益可能超过部分治疗疟疾的不良结局。
研究设计与样本
- 前瞻性观察性研究的Meta分析,检索Medline、Embase和Malaria in Pregnancy Library等电子数据库并联系研究者。
- 纳入5项研究共30618例妊娠,其中4项来自撒哈拉以南非洲(n=6666例妊娠,6个站点),1项来自泰国(n=23952)。
- 抗疟暴露通过自我报告或主动检测确定,并经处方、门诊卡和门诊登记确认。
- 采用Cox比例风险模型计算风险比,非洲研究采用个体参与者数据(IPD)Meta分析合并,再与泰国研究采用随机效应模型聚合数据Meta分析合并。
- 研究注册号:PROSPERO CRD42015032371。
主要发现
- 妊娠早期任何时间使用青蒿素(n=37/671)与奎宁(n=96/945)相比,流产风险无差异(aHR=0.73,95%CI 0.44-1.21,I²=0%,p=0.228)。
- 死产风险:青蒿素组n=10/654 vs 奎宁组n=11/615,aHR=0.29(95%CI 0.08-1.02),p=0.053。
- 流产和死产合并(妊娠丢失)风险aHR=0.58(95%CI 0.36-1.02),p=0.099。
- 胚胎敏感期(妊娠6-12周)青蒿素暴露的敏感性分析:流产aHR=1.04(95%CI 0.54-2.01,I²=0%,p=0.910);死产aHR=0.73(95%CI 0.26-2.06,p=0.551);妊娠丢失aHR=0.98(95%CI 0.52-2.04,p=0.603)。
- 重大先天畸形患病率:妊娠早期青蒿素暴露1.5%(95%CI 0.6%-3.5%)vs 奎宁暴露1.2%(95%CI 0.6%-2.4%)。
关键数值与推荐
- 主要结局为流产、死产和重大先天畸形。
- 青蒿素组流产n=37/671,奎宁组n=96/945,aHR=0.73(95%CI 0.44-1.21)。
- 青蒿素组死产n=10/654,奎宁组n=11/615,aHR=0.29(95%CI 0.08-1.02)。
- 青蒿素组重大先天畸形患病率1.5%(95%CI 0.6%-3.5%),奎宁组1.2%(95%CI 0.6%-2.4%)。
临床怎么用
- 作者认为3天青蒿素联合疗法治疗早期妊娠疟疾的获益可能超过部分治疗疟疾的不良结局,后者可因口服奎宁7天方案依从性差而发生。
局限性
- 非洲研究无法控制指示偏倚。
- 关于潜在混杂因素的数据匮乏。
- 检测先天畸形差异的统计效能有限。
- 未评估新生儿心血管缺陷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Animal embryotoxicity data, and the scarcity of safety data in human pregnancies, have prevented artemisinin derivatives from being recommended for malaria treatment in the first trimester except in lifesaving circumstances. We conducted a meta-analysis of prospective observational studies comparing the risk of miscarriage, stillbirth, and major congenital anomaly (primary outcomes) among first-trimester pregnancies treated with artemisinin derivatives versus quinine or no antimalarial treatment. METHODS AND FINDINGS: Electronic databases including Medline, Embase, and Malaria in Pregnancy Library were searched, and investigators contacted. Five studies involving 30,618 pregnancies were included; four from sub-Saharan Africa (n = 6,666 pregnancies, six sites) and one from Thailand (n = 23,952). Antimalarial exposures were ascertained by self-report or active detection and confirmed by prescriptions, clinic cards, and outpatient registers. Cox proportional hazards models, accounting for time under observation and gestational age at enrollment, were used to calculate hazard ratios. Individual participant data (IPD) meta-analysis was used to combine the African studies, and the results were then combined with those from Thailand using aggregated data meta-analysis with a random effects model. There was no difference in the risk of miscarriage associated with the use of artemisinins anytime during the first trimester (n = 37/671) compared with quinine (n = 96/945; adjusted hazard ratio [aHR] = 0.73 [95% CI 0.44, 1.21], I2 = 0%, p = 0.228), in the risk of stillbirth (artemisinins, n = 10/654; quinine, n = 11/615; aHR = 0.29 [95% CI 0.08-1.02], p = 0.053), or in the risk of miscarriage and stillbirth combined (pregnancy loss) (aHR = 0.58 [95% CI 0.36-1.02], p = 0.099). The corresponding risks of miscarriage, stillbirth, and pregnancy loss in a sensitivity analysis restricted to artemisinin exposures during the embryo sensitive period (6-12 wk gestation) were as follows: aHR = 1.04 (95% CI 0.54-2.01), I2 = 0%, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603. The prevalence of major congenital anomalies was similar for first-trimester artemisinin (1.5% [95% CI 0.6%-3.5%]) and quinine exposures (1.2% [95% CI 0.6%-2.4%]). Key limitations of the study include the inability to control for confounding by indication in the African studies, the paucity of data on potential confounders, the limited statistical power to detect differences in congenital anomalies, and the lack of assessment of cardiovascular defects in newborns. CONCLUSIONS: Compared to quinine, artemisinin treatment in the first trimester was not associated with an increased risk of miscarriage or stillbirth. While the data are limited, they indicate no difference in the prevalence of major congenital anomalies between treatment groups. The benefits of 3-d artemisinin combination therapy regimens to treat malaria in early pregnancy are likely to outweigh the adverse outcomes of partially treated malaria, which can occur with oral quinine because of the known poor adherence to 7-d regimens. REVIEW REGISTRATION: PROSPERO CRD42015032371.
引用
- Dellicour S, Sevene E, McGready R, et al. First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. PLoS Med. 2017. PMID: 28463996. doi:10.1371/journal.pmed.1002290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。